Skip to main content

Daliresp Disease Interactions

There are 3 disease interactions with Daliresp (roflumilast).

Major

Roflumilast (applies to Daliresp) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Roflumilast is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). Roflumilast is extensively metabolized via Phase I (cytochrome P450) and Phase II (conjugation) reactions. Clinicians should consider the risk-benefit of administering roflumilast to patients with mild liver impairment (Child-Pugh A).

References

  1. "Product Information. Daliresp (roflumilast)." Astra-Zeneca Pharmaceuticals (2011):
Moderate

Roflumilast (applies to Daliresp) depression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Anxiety/Stress

The use of roflumilast is associated with an increase in psychiatric adverse reactions. Instances of suicidal ideation and behavior, including completed suicide, have been observed in clinical trials. Before using roflumilast in patients with a history of depression and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits of treatment in all patients. Close monitoring for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes is recommended.

References

  1. "Product Information. Daliresp (roflumilast)." Astra-Zeneca Pharmaceuticals (2011):
Moderate

Roflumilast (applies to Daliresp) weight loss

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Weight Loss/Failure to Thrive

Weight loss is a common adverse reaction with the use of roflumilast. Patients treated with roflumilast should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, weight loss should be evaluated, and discontinuation of treatment should be considered. Care should be exercised when using this agent in patients at risk of weight loss.

References

  1. "Product Information. Daliresp (roflumilast)." Astra-Zeneca Pharmaceuticals (2011):

Daliresp drug interactions

There are 344 drug interactions with Daliresp (roflumilast).

Daliresp alcohol/food interactions

There is 1 alcohol/food interaction with Daliresp (roflumilast).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer